These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22424710)

  • 21. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
    Shen J; Huang C; Jiang L; Gao F; Wang Z; Zhang Y; Bai J; Zhou H; Chen Q
    Biochem Pharmacol; 2007 Jun; 73(12):1901-9. PubMed ID: 17445779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
    Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
    Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
    Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
    Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
    Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
    Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
    Subbiah V; Brown RE; McGuire MF; Buryanek J; Janku F; Younes A; Hong D
    Oncotarget; 2014 Jan; 5(1):95-102. PubMed ID: 24395633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine.
    Foell JL; Max D; Giersberg C; Korholz D; Staege MS
    Anticancer Res; 2008; 28(2A):887-94. PubMed ID: 18507033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
    Hu Y; Lu W; Chen G; Zhang H; Jia Y; Wei Y; Yang H; Zhang W; Fiskus W; Bhalla K; Keating M; Huang P; Garcia-Manero G
    Blood; 2010 Oct; 116(15):2732-41. PubMed ID: 20566897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.
    Seitz V; Thomas PE; Zimmermann K; Paul U; Ehlers A; Joosten M; Dimitrova L; Lenze D; Sommerfeld A; Oker E; Leser U; Stein H; Hummel M
    Haematologica; 2011 Jun; 96(6):863-70. PubMed ID: 21393330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
    Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
    Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
    Pettke A; Hotfilder M; Clemens D; Klco-Brosius S; Schaefer C; Potratz J; Dirksen U
    Anticancer Drugs; 2016 Nov; 27(10):1001-10. PubMed ID: 27487911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
    Huang WJ; Tang YA; Chen MY; Wang YJ; Hu FH; Wang TW; Chao SW; Chiu HW; Yeh YL; Chang HY; Juan HF; Lin P; Wang YC
    Cancer Lett; 2014 Apr; 346(1):84-93. PubMed ID: 24355296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
    Iwamoto M; Friedman EJ; Sandhu P; Agrawal NG; Rubin EH; Wagner JA
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):493-508. PubMed ID: 23820962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
    Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC
    Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.